PLK1 and hepatocellular carcinoma: Both PLK1 and RAS are targets of the novel and effective small molecule inhibitor rigosertib (Figures 1–3), and we found that PLK1 and HRAS are commonly upregulated in HCC (Figure 4) and independently affect patient overall survival (Figure 5) with interesting differences among different ethnic background.